Logo image of SNOA

SONOMA PHARMACEUTICALS INC (SNOA) Stock Fundamental Analysis

NASDAQ:SNOA - Nasdaq - US83558L3033 - Common Stock - Currency: USD

3.21  -0.11 (-3.31%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SNOA. SNOA was compared to 198 industry peers in the Pharmaceuticals industry. While SNOA has a great health rating, there are worries on its profitability. SNOA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SNOA had negative earnings in the past year.
In the past year SNOA had a positive cash flow from operations.
SNOA had negative earnings in each of the past 5 years.
In the past 5 years SNOA always reported negative operating cash flow.
SNOA Yearly Net Income VS EBIT VS OCF VS FCFSNOA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

1.2 Ratios

With a Return On Assets value of -27.42%, SNOA perfoms like the industry average, outperforming 54.55% of the companies in the same industry.
With a Return On Equity value of -76.96%, SNOA perfoms like the industry average, outperforming 45.45% of the companies in the same industry.
Industry RankSector Rank
ROA -27.42%
ROE -76.96%
ROIC N/A
ROA(3y)-30.51%
ROA(5y)-28.12%
ROE(3y)-67.28%
ROE(5y)-66.88%
ROIC(3y)N/A
ROIC(5y)N/A
SNOA Yearly ROA, ROE, ROICSNOA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

SNOA's Gross Margin of 35.98% is in line compared to the rest of the industry. SNOA outperforms 59.09% of its industry peers.
In the last couple of years the Gross Margin of SNOA has declined.
The Profit Margin and Operating Margin are not available for SNOA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 35.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.79%
GM growth 5Y-4.46%
SNOA Yearly Profit, Operating, Gross MarginsSNOA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

7

2. Health

2.1 Basic Checks

SNOA does not have a ROIC to compare to the WACC, probably because it is not profitable.
SNOA has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, SNOA has less shares outstanding
Compared to 1 year ago, SNOA has an improved debt to assets ratio.
SNOA Yearly Shares OutstandingSNOA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
SNOA Yearly Total Debt VS Total AssetsSNOA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

Based on the Altman-Z score of -19.11, we must say that SNOA is in the distress zone and has some risk of bankruptcy.
SNOA's Altman-Z score of -19.11 is on the low side compared to the rest of the industry. SNOA is outperformed by 80.81% of its industry peers.
There is no outstanding debt for SNOA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z -19.11
ROIC/WACCN/A
WACC9.82%
SNOA Yearly LT Debt VS Equity VS FCFSNOA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 3.34 indicates that SNOA has no problem at all paying its short term obligations.
SNOA has a Current ratio (3.34) which is in line with its industry peers.
A Quick Ratio of 2.49 indicates that SNOA has no problem at all paying its short term obligations.
The Quick ratio of SNOA (2.49) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.34
Quick Ratio 2.49
SNOA Yearly Current Assets VS Current LiabilitesSNOA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for SNOA have decreased strongly by -59.77% in the last year.
Looking at the last year, SNOA shows a quite strong growth in Revenue. The Revenue has grown by 13.53% in the last year.
Measured over the past years, SNOA shows a decrease in Revenue. The Revenue has been decreasing by -7.66% on average per year.
EPS 1Y (TTM)-59.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.63%
Revenue 1Y (TTM)13.53%
Revenue growth 3Y-11.91%
Revenue growth 5Y-7.66%
Sales Q2Q%13.58%

3.2 Future

The Earnings Per Share is expected to decrease by -41.70% on average over the next years. This is quite bad
Based on estimates for the next years, SNOA will show a quite strong growth in Revenue. The Revenue will grow by 15.09% on average per year.
EPS Next Y24.72%
EPS Next 2Y-41.7%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year5.59%
Revenue Next 2Y15.09%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SNOA Yearly Revenue VS EstimatesSNOA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M
SNOA Yearly EPS VS EstimatesSNOA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2017 2018 2019 2021 2024 2025 2026 0 -500 -1K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SNOA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SNOA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNOA Price Earnings VS Forward Price EarningsSNOA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, SNOA is valued a bit cheaper than the industry average as 78.28% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 40.31
EV/EBITDA N/A
SNOA Per share dataSNOA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

SNOA's earnings are expected to decrease with -41.70% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.7%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SNOA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SONOMA PHARMACEUTICALS INC

NASDAQ:SNOA (5/23/2025, 8:56:24 PM)

3.21

-0.11 (-3.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-05 2025-02-05/amc
Earnings (Next)06-16 2025-06-16/amc
Inst Owners1.26%
Inst Owner Change63.98%
Ins Owners1.31%
Ins Owner Change0%
Market Cap5.20M
Analysts85.71
Price Target17.34 (440.19%)
Short Float %5.09%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.32%
Min EPS beat(2)10.49%
Max EPS beat(2)42.16%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-12.89%
Min Revenue beat(2)-13.93%
Max Revenue beat(2)-11.85%
Revenue beat(4)0
Avg Revenue beat(4)-14.18%
Min Revenue beat(4)-15.63%
Max Revenue beat(4)-11.85%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.37
P/FCF 40.31
P/OCF 32.71
P/B 1.07
P/tB 1.07
EV/EBITDA N/A
EPS(TTM)-3.96
EYN/A
EPS(NY)-1.82
Fwd EYN/A
FCF(TTM)0.08
FCFY2.48%
OCF(TTM)0.1
OCFY3.06%
SpS8.63
BVpS3.01
TBVpS3.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.42%
ROE -76.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 35.98%
FCFM 0.92%
ROA(3y)-30.51%
ROA(5y)-28.12%
ROE(3y)-67.28%
ROE(5y)-66.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.79%
GM growth 5Y-4.46%
F-Score5
Asset Turnover1.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 20.27%
Cap/Sales 0.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.34
Quick Ratio 2.49
Altman-Z -19.11
F-Score5
WACC9.82%
ROIC/WACCN/A
Cap/Depr(3y)97.01%
Cap/Depr(5y)87.41%
Cap/Sales(3y)1.09%
Cap/Sales(5y)1.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-59.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.63%
EPS Next Y24.72%
EPS Next 2Y-41.7%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)13.53%
Revenue growth 3Y-11.91%
Revenue growth 5Y-7.66%
Sales Q2Q%13.58%
Revenue Next Year5.59%
Revenue Next 2Y15.09%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y102.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y103.11%
OCF growth 3YN/A
OCF growth 5YN/A